{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T21:23:42Z","timestamp":1749417822138},"reference-count":85,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2021]]},"DOI":"10.3960\/jslrt.21003","type":"journal-article","created":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T22:15:31Z","timestamp":1631225731000},"page":"182-191","source":"Crossref","is-referenced-by-count":7,"title":["Diagnostic utility of programmed cell death ligand 1 (clone SP142) immunohistochemistry for malignant lymphoma and lymphoproliferative disorders: A brief review"],"prefix":"10.3960","volume":"61","author":[{"given":"Ayako","family":"Sakakibara","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Kohno","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eri","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Tsuyuki","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoko","family":"Shimada","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyuki","family":"Shimada","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Satou","sequence":"additional","affiliation":[{"name":"Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taishi","family":"Takahara","sequence":"additional","affiliation":[{"name":"Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Ohashi","sequence":"additional","affiliation":[{"name":"Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emiko","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiichi","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeo","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Asano","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Nagano Prefectural Suzaka Hospital, Nagano, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Roemer MGM, Advani RH, Ligon AH <i>et al.<\/i> PD-L1 and PD-L2 Genetic alterations define classical Hodgkin lymphoma and predict outcome. J Clin Oncol. 2016; 34: 2690-2697.","DOI":"10.1200\/JCO.2016.66.4482"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 De Goycoechea D, Stalder G, Martins F, Duchosal MA. Immune checkpoint inhibition in classical Hodgkin lymphoma: from early achievements towards new perspectives. J Oncol. 2019; 2019: 9513701.","DOI":"10.1155\/2019\/9513701"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Piris MA, Medeiros LJ, Chang KC. Hodgkin lymphoma: a review of pathological features and recent advances in pathogenesis. Pathology. 2020; 52: 154-165.","DOI":"10.1016\/j.pathol.2019.09.005"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Ilcus C, Bagacean C, Tempescul A <i>et al.<\/i> Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies. OncoTargets Ther. 2017; 10: 2349-2363.","DOI":"10.2147\/OTT.S133385"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Nicolae A, Pittaluga S, Abdullah S <i>et al.<\/i> EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment. Blood. 2015; 126: 863-872.","DOI":"10.1182\/blood-2015-02-630632"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Kiyasu J, Miyoshi H, Hirata A <i>et al.<\/i> Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood. 2015; 126: 2193-2201.","DOI":"10.1182\/blood-2015-02-629600"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Sakakibara A, Kohno K, Eladl AE <i>et al.<\/i> Immunohistochemical assessment of the diagnostic utility of PD-L1: a preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells. Histopathology. 2018; 72: 1156-1163.","DOI":"10.1111\/his.13475"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Gupta GK, Jaffe ES, Pittaluga S. A study of PD-L1 expression in intravascular large B cell lymphoma: correlation with clinical and pathological features. Histopathology. 2019; 75: 282-286.","DOI":"10.1111\/his.13870"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Panjwani PK, Charu V, DeLisser M <i>et al.<\/i> Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes. Hum Pathol. 2018; 71: 91-99.","DOI":"10.1016\/j.humpath.2017.10.029"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Carbone A, Gloghini A, Carlo-Stella C. Are EBV-related and EBV-unrelated Hodgkin lymphomas different with regard to susceptibility to checkpoint blockade? Blood. 2018; 132: 17-22.","DOI":"10.1182\/blood-2018-02-833806"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Green MR, Rodig S, Juszczynski P <i>et al.<\/i> Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res. 2012; 18: 1611-1618.","DOI":"10.1158\/1078-0432.CCR-11-1942"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Green MR, Monti S, Rodig SJ <i>et al.<\/i> Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010; 116: 3268-3277.","DOI":"10.1182\/blood-2010-05-282780"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Uccini S, Al-Jadiry MF, Pepe G <i>et al.<\/i> PD-L1 expression in pediatric Epstein-Barr virus positive classic Hodgkin lymphoma is not associated with 9p24.1 amplification. Pediatr Blood Cancer. 2019; 66: e27757.","DOI":"10.1002\/pbc.27757"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Menter T, Bodmer-Haecki A, Dirnhofer S, Tzankov A. Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas. Hum Pathol. 2016; 54: 17-24.","DOI":"10.1016\/j.humpath.2016.03.005"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Strickler JG, Michie SA, Warnke RA, Dorfman RF. The \u201csyncytial variant\u201d of nodular sclerosing Hodgkin\u2019s disease. Am J Surg Pathol. 1986; 10: 470-477.","DOI":"10.1097\/00000478-198607000-00004"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Ben-Yehuda-Salz D, Polliack A, Ben-Yehuda A, Ron N, Okon E. Syncytial variant of nodular sclerosing Hodgkin\u2019s disease. A new clinicopathologic entity. Cancer. 1990; 65: 1167-1172.","DOI":"10.1002\/1097-0142(19900301)65:5<1167::AID-CNCR2820650523>3.0.CO;2-V"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Drakos E, Rassidakis GZ, Leventaki V <i>et al.<\/i> Nodular lymphocyte predominant Hodgkin lymphoma with clusters of LP Cells, acute inflammation, and fibrosis: A syncytial variant. Am J Surg Pathol. 2009; 33: 1725-1731.","DOI":"10.1097\/PAS.0b013e3181b27765"},{"key":"18","unstructured":"18 Gibson B, Podoll MB, Baumgartner EM, Maley DH. Syncytial variant of nodular sclerosis classical Hodgkin lymphoma of the terminal ileum in a patient with longstanding Crohn\u2019s disease. Ann Clin Lab Sci. 2016; 46: 219-221."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Kohno K, Sakakibara A, Iwakoshi A <i>et al.<\/i> Syncytial variant of classic Hodgkin lymphoma: four cases diagnosed with the aid of CD274\/programmed cell death ligand 1 immunohistochemistry. Pathol Int. 2020; 70: 108-115.","DOI":"10.1111\/pin.12888"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Hollander P, Amini RM, Ginman B <i>et al.<\/i> Expression of PD-1 and PD-L1 increase in consecutive biopsies in patients with classical Hodgkin lymphoma. PLoS One. 2018; 13: e0204870.","DOI":"10.1371\/journal.pone.0204870"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Wang HW, Balakrishna JP, Pittaluga S, Jaffe ES. Diagnosis of Hodgkin lymphoma in the modern era. Br J Haematol. 2019; 184: 45-59.","DOI":"10.1111\/bjh.15614"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Kohno K, Suzuki Y, Elsayed AA <i>et al.<\/i> Immunohistochemical assessment of the diagnostic utility of PD-L1 (clone SP142) for methotrexate-associated lymphoproliferative disorders with an emphasis of neoplastic PD-L1 (clone SP142)-positive classic Hodgkin lymphoma type. Am J Clin Pathol. 2020; 153: 571-582.","DOI":"10.1093\/ajcp\/aqz198"},{"key":"23","unstructured":"23 Jaffe ES, Stein H, Swerdlow SH. Classic Hodgkin lynphoma. In : Swerdlow SH, Campo E, Harris NL, <i>et al<\/i>. (eds) : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed, Lyon, IARC. 2017; pp. 435-442."},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Spina M, Carbone A, Gloghini A <i>et al.<\/i> Hodgkin\u2019s disease in patients with HIV infection. Adv Hematol. 2011; 2011: 402682.","DOI":"10.1155\/2011\/402682"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Ding J, Kumar AJ, Wilding E, Lee ST, Law JY. Multi-organ failure as the initial presentation of lymphocyte-depleted Hodgkin lymphoma in two patients with human immunodeficiency virus. Acta Haematol. 2020; 143: 184-188.","DOI":"10.1159\/000500222"},{"key":"26","unstructured":"26 Said J, Cesarman E, Rosenwald A, Harris NL. Lymphomas Associated Hiv Infection. In : Swerdlow SH, Campo E, Harris NL, <i>et al<\/i>. (eds) : WHO Classification of Tumours of Haematopietic and Lymphoid Tissues. 4th ed, Lyon, IARC. 2017; pp. 449-452."},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Dojcinov SD, Fend F, Quintanilla-Martinez L. EBV-positive lymphoproliferations of B- T- and NK-cell derivation in non-immunocompromised hosts. Pathogens. 2018; 7: 28.","DOI":"10.3390\/pathogens7010028"},{"key":"28","unstructured":"28 Nakamura S, Jaffe ES, Swerdlow SH. Ebv-positive diffuse large B-cell lymphoma, not otherwise specified (Nos). In : Swerdlow SH, Campo E, Harris NL, <i>et al<\/i>. (eds) : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed, Lyon, IARC. 2017; pp. 304-306."},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Sakakibara A, Kohno K, Ishikawa E <i>et al.<\/i> Age-related EBV-associated B-cell lymphoproliferative disorders and other EBV + lymphoproliferative diseases: new insights into immune escape and immunodeficiency through staining with anti-PD-L1 antibody clone SP142. Pathol Int. 2020; 70: 481-492.","DOI":"10.1111\/pin.12946"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Oyama T, Ichimura K, Suzuki R <i>et al.<\/i> Senile EBV+ B-cell lymphoproliferative disorders: A clinicopathologic study of 22 patients. Am J Surg Pathol. 2003; 27: 16-26.","DOI":"10.1097\/00000478-200301000-00003"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Oyama T, Yamamoto K, Asano N <i>et al.<\/i> Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: A study of 96 patients. Clin Cancer Res. 2007; 13: 5124-5132.","DOI":"10.1158\/1078-0432.CCR-06-2823"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Shimoyama Y, Yamamoto K, Asano N <i>et al.<\/i> Age-related Epstein-Barr virus-associated B-cell lymphoproliferative disorders: special references to lymphomas surrounding this newly recognized clinicopathologic disease. Cancer Sci. 2008; 99: 1085-1091.","DOI":"10.1111\/j.1349-7006.2008.00813.x"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Asano N, Yamamoto K, Tamaru J <i>et al.<\/i> Age-related Epstein-Barr virus (EBV)\u2013associated B-cell lymphoproliferative disorders: comparison with EBV-positive classic Hodgkin lymphoma in elderly patients. Blood. 2009; 113: 2629-2636.","DOI":"10.1182\/blood-2008-06-164806"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Shimoyama Y, Asano N, Kojima M <i>et al.<\/i> Age-related EBV-associated B-cell lymphoproliferative disorders: diagnostic approach to a newly recognized clinicopathological entity. Pathol Int. 2009; 59: 835-843.","DOI":"10.1111\/j.1440-1827.2009.02466.x"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Dojcinov SD, Venkataraman G, Pittaluga S <i>et al.<\/i> Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma. Blood. 2011; 117: 4726-4735.","DOI":"10.1182\/blood-2010-12-323238"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Chihara D, Ito H, Matsuda T <i>et al.<\/i> Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol. 2014; 164: 536-545.","DOI":"10.1111\/bjh.12659"},{"key":"37","unstructured":"37 Banks PM. The distinction of Hodgkin\u2019s disease from T cell lymphoma. Semin Diagn Pathol. 1992; 9: 279-283."},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Quintanilla-Martinez L, Fend F, Moguel LR <i>et al.<\/i> Peripheral T-cell lymphoma with Reed-Sternberg-like cells of B-cell phenotype and genotype associated with Epstein-Barr virus infection. Am J Surg Pathol. 1999; 23: 1233-1240.","DOI":"10.1097\/00000478-199910000-00008"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39 Nicolae A, Pittaluga S, Venkataraman G <i>et al.<\/i> Peripheral T-cell lymphomas of follicular T-helper cell derivation with Hodgkin\/Reed-Sternberg cells of B-cell lineage: both EBV-positive and EBV-negative variants exist. Am J Surg Pathol. 2013; 37: 816-826.","DOI":"10.1097\/PAS.0b013e3182785610"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40 de Leval L, Gisselbrecht C, Gaulard P. Advances in the understanding and management of angioimmunoblastic T-cell lymphoma. Br J Haematol. 2010; 148: 673-689.","DOI":"10.1111\/j.1365-2141.2009.08003.x"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41 Eladl AE, Satou A, Elsayed AA <i>et al.<\/i> Clinicopathological study of 30 cases of peripheral T-cell lymphoma with Hodgkin and Reed-Sternberg-like B-cells from Japan. Am J Surg Pathol. 2017; 41: 506-516.","DOI":"10.1097\/PAS.0000000000000813"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42 Moroch J, Copie-Bergman C, de Leval L <i>et al.<\/i> Follicular peripheral T-cell lymphoma expands the spectrum of classical Hodgkin lymphoma mimics. Am J Surg Pathol. 2012; 36: 1636-1646.","DOI":"10.1097\/PAS.0b013e318268d9ff"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43 Alikhan M, Song JY, Sohani AR <i>et al.<\/i> Peripheral T-cell lymphomas of follicular helper T-cell type frequently display an aberrant CD3(\u2212\/dim) CD4(+) population by flow cytometry: an important clue to the diagnosis of a Hodgkin lymphoma mimic. Mod Pathol. 2016; 29: 1173-1182.","DOI":"10.1038\/modpathol.2016.113"},{"key":"44","unstructured":"44 Jaffe ES, Stein H, Swerdlow SH, et al. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classic Hodgkin lymphoma. In : Swerdlow SH, Campo E, Harris NL, <i>et al<\/i>. (eds) : WHO Classification of Tumours of Haematopietic and Lymphoid Tissues. 4th ed, Lyon, IARC. 2017; pp. 342-344."},{"key":"45","doi-asserted-by":"crossref","unstructured":"45 Pilichowska M, Pittaluga S, Ferry JA <i>et al.<\/i> Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL. Blood Adv. 2017; 1: 2600-2609.","DOI":"10.1182\/bloodadvances.2017009472"},{"key":"46","unstructured":"46 Gaulard P, Harris NL, Pileri SA, et al. Primary mediastinal (thymic) large B-cell lymphoma. In : Swerdlow SH, Campo E, Harris NL, <i>et al<\/i>. (eds) : WHO Classification of Tumours of Haematopietic and Lymphoid Tissues. 4th ed, Lyon, IARC. 2017; pp. 314-316."},{"key":"47","doi-asserted-by":"crossref","unstructured":"47 Traverse-Glehen A, Pittaluga S, Gaulard P <i>et al.<\/i> Mediastinal gray zone lymphoma: the missing link between classic Hodgkin\u2019s lymphoma and mediastinal large B-cell lymphoma. Am J Surg Pathol. 2005; 29: 1411-1421.","DOI":"10.1097\/01.pas.0000180856.74572.73"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48 Tanaka Y, Maeshima AM, Nomoto J <i>et al.<\/i> Expression pattern of PD-L1 and PD-L2 in classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, and gray zone lymphoma. Eur J Haematol. 2018; 100: 511-517.","DOI":"10.1111\/ejh.13033"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49 Sarkozy C, Copie-Bergman C, Damotte D <i>et al.<\/i> Gray-zone lymphoma between cHL and large B-cell lymphoma: A histopathologic series from the LYSA. Am J Surg Pathol. 2019; 43: 341-351.","DOI":"10.1097\/PAS.0000000000001198"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50 Xerri L, Chetaille B, Serriari N <i>et al.<\/i> Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma\/chronic lymphocytic leukemia. Hum Pathol. 2008; 39: 1050-1058.","DOI":"10.1016\/j.humpath.2007.11.012"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51 Chen BJ, Chapuy B, Ouyang J <i>et al.<\/i> PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res. 2013; 19: 3462-3473.","DOI":"10.1158\/1078-0432.CCR-13-0855"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52 Andorsky DJ, Yamada RE, Said J <i>et al.<\/i> Programmed death ligand 1 is expressed by non-Hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin Cancer Res. 2011; 17: 4232-4244.","DOI":"10.1158\/1078-0432.CCR-10-2660"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53 Shi M, Roemer MGM, Chapuy B <i>et al.<\/i> Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain. Am J Surg Pathol. 2014; 38: 1715-1723.","DOI":"10.1097\/PAS.0000000000000297"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54 Sakakibara A, Kohno K, Iwakoshi A <i>et al.<\/i> Diagnostic utility of programmed cell death ligand 1 (clone SP142) in mediastinal composite lymphoma: A report of two cases. Pathol Int. 2020; 70: 116-122.","DOI":"10.1111\/pin.12891"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55 . The World Health Organization classification of malignant lymphomas in Japan: incidence of recently recognized entities. Pathol Int. 2000; 50: 696-702.","DOI":"10.1046\/j.1440-1827.2000.01108.x"},{"key":"56","unstructured":"56 Gascoyne RD, Campo E, Jaffe ES, et al. Diffuse large B-cell lymphoma, Nos. In : Swerdlow SH, Campo E, Harris NL, <i>et al<\/i>. (eds) : WHO Classification of Tumours of Haematopietic and Lymphoid Tissues. 4th ed, Lyon, IARC. 2017; pp. 291-297."},{"key":"57","doi-asserted-by":"crossref","unstructured":"57 Li M, Liu Y, Wang Y <i>et al.<\/i> Anaplastic variant of diffuse large B-cell lymphoma displays intricate genetic alterations and distinct biological features. Am J Surg Pathol. 2017; 41: 1322-1332.","DOI":"10.1097\/PAS.0000000000000836"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58 Megahed NA, Kohno K, Sakakibara A <i>et al.<\/i> Anaplastic variant of diffuse large B-cell lymphoma: reappraisal as a nodal disease with sinusoidal involvement. Pathol Int. 2019; 69: 697-705.","DOI":"10.1111\/pin.12871"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59 Lai R, Medeiros LJ, Dabbagh L, Formenti KS, Coupland RW. Sinusoidal CD30-positive large B-cell lymphoma: A morphologic mimic of anaplastic large cell lymphoma. Mod Pathol. 2000; 13: 223-228.","DOI":"10.1038\/modpathol.3880041"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60 Xu J, Li P, Chai J <i>et al.<\/i> The clinicopathological and molecular features of sinusoidal large B-cell lymphoma. Mod Pathol. 2021; 34: 922-933.","DOI":"10.1038\/s41379-020-00685-7"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61 Kohno K, Suzuki Y, Harada T <i>et al.<\/i> Nodal diffuse large B-cell lymphoma with neoplastic PD-L1 positivity, but without EBV association: three cases highlighting an aspect of gray zone lymphoma. Pathol Int. 2020; 70: 695-697.","DOI":"10.1111\/pin.12982"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62 Yamaguchi M, Nakamura N, Suzuki R <i>et al.<\/i> De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients. Haematologica. 2008; 93: 1195-1202.","DOI":"10.3324\/haematol.12810"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63 Suzuki Y, Sakakibara A, Shimada K <i>et al.<\/i> Immune evasion-related extranodal large B-cell lymphoma: A report of six patients with neoplastic PD-L1-positive extranodal diffuse large B-cell lymphoma. Pathol Int. 2019; 69: 13-20.","DOI":"10.1111\/pin.12742"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64 Gravelle P, Burroni B, P\u00e9ricart S <i>et al.<\/i> Mechanisms of PD-1\/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies. Oncotarget. 2017; 8: 44960-44975.","DOI":"10.18632\/oncotarget.16680"},{"key":"65","unstructured":"65 Swerdlow SH, Campo E, Harris NL, et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed, Lyon, International Agency for Research on Cancer (IARC). 2017."},{"key":"66","doi-asserted-by":"crossref","unstructured":"66 Ponzoni M, Campo E, Nakamura S. Intravascular large B-cell lymphoma: a chameleon with multiple faces and many masks. Blood. 2018; 132: 1561-1567.","DOI":"10.1182\/blood-2017-04-737445"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67 Jaffe ES. Navigating the cutaneous B-cell lymphomas: avoiding the rocky shoals. Mod Pathol. 2020; 33: 96-106.","DOI":"10.1038\/s41379-019-0385-7"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68 Sukswai N, Lyapichev K, Khoury JD, Medeiros LJ. Diffuse large B-cell lymphoma variants: an update. Pathology. 2020; 52: 53-67.","DOI":"10.1016\/j.pathol.2019.08.013"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69 King RL, Goodlad JR, Calaminici M <i>et al.<\/i> Lymphomas arising in immune-privileged sites: insights into biology, diagnosis, and pathogenesis. Virchows Arch. 2020; 476: 647-665.","DOI":"10.1007\/s00428-019-02698-3"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70 Shimada K, Yamaguchi M, Atsuta Y <i>et al.<\/i> Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020; 21: 593-602.","DOI":"10.1016\/S1470-2045(20)30059-0"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71 Vitiello P, Sica A, Ronchi A <i>et al.<\/i> Primary cutaneous B-cell lymphomas: an update. Front Oncol. 2020; 10: 651.","DOI":"10.3389\/fonc.2020.00651"},{"key":"72","unstructured":"72 Nakamura S, Ponzoni M, Campo E. Intravascular large B-cell lymphoma. In : Swerdlow SH, Campo E, Harris NL, <i>et al<\/i>. (eds) : WHO Classification of Tumours of Haematopietic and Lymphoid Tissues. 4th ed, Lyon, IARC. 2017; pp. 317-318."},{"key":"73","doi-asserted-by":"crossref","unstructured":"73 Sakakibara A, Inagaki Y, Imaoka E <i>et al.<\/i> Autopsy case report of intravascular large B-cell lymphoma with neoplastic PD-L1 expression. J Clin Exp Hematop. 2018; 58: 32-35.","DOI":"10.3960\/jslrt.17037"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74 Ishikawa E, Kato S, Shimada K <i>et al.<\/i> Clinicopathological analysis of primary intestinal diffuse large B-cell lymphoma: prognostic evaluation of CD5, PD-L1, and Epstein-Barr virus on tumor cells. Cancer Med. 2018; 7: 6051-6063.","DOI":"10.1002\/cam4.1875"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75 Sakakibara A, Inagaki Y, Imaoka E <i>et al.<\/i> Divergence and heterogeneity of neoplastic PD-L1 expression: two autopsy case reports of intravascular large B-cell lymphoma. Pathol Int. 2019; 69: 148-154.","DOI":"10.1111\/pin.12757"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76 Suzuki Y, Kohno K, Matsue K <i>et al.<\/i> PD-L1 (SP142) expression in neoplastic cells predicts a poor prognosis for patients with intravascular large B-cell lymphoma treated with rituximab-based multi-agent chemotherapy. Cancer Med. 2020; 9: 4768-4776.","DOI":"10.1002\/cam4.3104"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77 Shimada K, Yoshida K, Suzuki Y <i>et al.<\/i> Frequent genetic alterations in immune checkpoint\u2013related genes in intravascular large B-cell lymphoma. Blood. 2021; 137: 1491-1502.","DOI":"10.1182\/blood.2020007245"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78 Ni X, Song Q, Cassady K <i>et al.<\/i> PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells. J Clin Invest. 2017; 127: 1960-1977.","DOI":"10.1172\/JCI91138"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79 Jin Y, Chauhan SK, El Annan J <i>et al.<\/i> A novel function for programmed death ligand-1 regulation of angiogenesis. Am J Pathol. 2011; 178: 1922-1929.","DOI":"10.1016\/j.ajpath.2010.12.027"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80 Ishikawa E, Tanaka T, Shimada K <i>et al.<\/i> A prognostic model, including the EBV status of tumor cells, for primary gastric diffuse large B-cell lymphoma in the rituximab era. Cancer Med. 2018; 7: 3510-3520.","DOI":"10.1002\/cam4.1595"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81 Ishikawa E, Nakamura M, Shimada K <i>et al.<\/i> Prognostic impact of PD-L1 expression in primary gastric and intestinal diffuse large B-cell lymphoma. J Gastroenterol. 2020; 55: 39-50.","DOI":"10.1007\/s00535-019-01616-3"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82 McCord R, Bolen CR, Koeppen H <i>et al.<\/i> PD-L1 and tumor-associated macrophages in de novo DLBCL. Blood Adv. 2019; 3: 531-540.","DOI":"10.1182\/bloodadvances.2018020602"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83 Miyoshi H, Kiyasu J, Kato T <i>et al.<\/i> PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia\/lymphoma. Blood. 2016; 128: 1374-1381.","DOI":"10.1182\/blood-2016-02-698936"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84 Asano N, Miyoshi H, Kato T <i>et al.<\/i> Expression pattern of immunosurveillance-related antigen in adult T cell leukaemia\/lymphoma. Histopathology. 2018; 72: 945-954.","DOI":"10.1111\/his.13461"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85 Tsuyuki Y, Ishikawa E, Kohno K <i>et al.<\/i> Expression of programmed cell death ligand-1 by immune cells in the microenvironment is a favorable prognostic factor for primary diffuse large B-cell lymphoma of the central nervous system. Neuropathology. 2021; 41: 99-108.","DOI":"10.1111\/neup.12705"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/61\/4\/61_21003\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T05:38:52Z","timestamp":1640410732000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/61\/4\/61_21003\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":85,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.21003","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]},"article-number":"21003"}}